You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)舒格利單抗聯合療法三期臨床數據於期刊發表
阿思達克 06-19 08:43
基石藥業(02616.HK)公布,旗下天然G型免疫球蛋白4(IgG4)單抗藥物舒格利單抗,聯合含鉑化療一線治療鱗狀和非鱗狀IV期非小細胞肺癌(非致癌基因驅動型)的三期臨床研究,其長期生存數據已於國際醫學期刊《柳葉刀.腫瘤學》中發表。 數據顯示,聯合療法令研究人群的中位總生存期延長至25.2個月,對比對照組患者為16.9個月,四年生存率從17.3%提升至32.1%。 基石藥業首席執行官、研發總裁及執行董事楊建新指,研究為舒格利單抗聯合化療的長期生存獲益提供關鍵依據,並鞏固了該療法在中國及歐洲轉移性NSCLC治療格局中的地位,公司正與合作夥伴加速該療法在全球關鍵市場的商業化落地。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account